Hairy cell leukemia-variant treated with 2-Chlorodeoxyadenosine-a report of three cases

Three patients with B-prolymphocytic variant of HCL (HCL-V) were treated with a chlorinated purine analogue, 2-chlorodeoxyadenosine, at a daily dosage of 0.12 mg/kg in 2-hour intravenous infusion for 5 consecutive days. Partial remission was achieved in only 1 patient, who relapsed after 6 months. T...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 1997-01, Vol.25 (3-4), p.381-385
Main Authors: Blasi ska-Morawiec, M., Robak, T., Krykowski, E., Hellmann, A., Urba ska-Ry, H.
Format: Article
Language:English
Subjects:
2-chlorodeoxyadenosine
Aged
Antigens, Surface - metabolism
Antineoplastic Agents - therapeutic use
Cladribine - therapeutic use
Drug Resistance, Neoplasm
Female
Hairy cell leukemia variant
Humans
Leukemia, Hairy Cell - drug therapy
Leukemia, Hairy Cell - mortality
Male
Middle Aged
Recurrence
Remission Induction
Spleen - pathology
therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Three patients with B-prolymphocytic variant of HCL (HCL-V) were treated with a chlorinated purine analogue, 2-chlorodeoxyadenosine, at a daily dosage of 0.12 mg/kg in 2-hour intravenous infusion for 5 consecutive days. Partial remission was achieved in only 1 patient, who relapsed after 6 months. Two other patients did not respond to the treatment. HCL-V is a distinct clinicopathological entity which seems to be resistant to various therapeutic modalities. However, further observations are necessary in order to establish the efficacy of 2-CdA in the treatment of HCL-V.
ISSN:1042-8194
1029-2403
DOI:10.3109/10428199709114177